Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury

BackgroundWe investigated the neuroprotective properties of levosimendan, a novel inodilator, in an in vitro model of traumatic brain injury.MethodsOrganotypic hippocampal brain slices from mouse pups were subjected to a focal mechanical trauma. Slices were treated after the injury with three different concentrations of levosimendan (0.001, 0.01 and 0.1 μM) and compared to vehicle-treated slices. After 72 hrs, the trauma was quantified using propidium iodide to mark the injured cells.ResultsA significant dose-dependent reduction of both total and secondary tissue injury was observed in cells treated with either 0.01 or 0.1 μM levosimendan compared to vehicle-treated slices.ConclusionLevosimendan represents a promising new pharmacological tool for neuroprotection after brain injury and warrants further investigation in an in vivo model.

• Publication year

  2010

• Venue

  BMC Neurology

• Publication date

  2010-10-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/1471-2377-10-97PMID 20964834PMCID 2978146
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti‐ischemic effects of inotropic agents in experimental right ventricular infarction

  2009cited by this paper
• Argon: Neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury

  2009cited by this paper
• Propofol: neuroprotection in an in vitro model of traumatic brain injury

  2009cited by this paper
• Research Propofol: neuroprotection in an in vitro model of traumatic brain

  2009cited by this paper
• Protection of the Spinal Cord from Ischemia: Comparative Effects of Levosimendan and Iloprost

  2008cited by this paper
• The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury*

  2008cited by this paper
• Traumatic brain injury: assessment, resuscitation and early management.

  2007influential reference
• Levosimendan improves the initial outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest

  2007cited by this paper
• MitoKATP opener, diazoxide, reduces neuronal damage after middle cerebral artery occlusion in the rat

  2002cited by this paper
• Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities.

  2002cited by this paper
• MitoK(ATP) opener, diazoxide, reduces neuronal damage after middle cerebral artery occlusion in the rat.

  2002cited by this paper
• Markers for neuronal degeneration in organotypic slice cultures.

  1999cited by this paper
• Mechanisms and Effects of Intracellular Calcium Buffering on Neuronal Survival in Organotypic Hippocampal Cultures Exposed to Anoxia/Aglycemia or to Excitotoxins

  1997cited by this paper

• The Role of Levosimendan in Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest.

  2025cites this paper
• Protective effects of levosimendan in scopolamineinduced mice model of Alzheimer's disease

  2024cites this paper
• The Impact of Inotropes and Vasopressors on Cerebral Oxygenation in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage: A Narrative Review

  2024cites this paper
• Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in TauP301L-BiFC mice

  2023cites this paper
• The Use of Levosimendan for the Treatment of Heart Failure and its Potential Organoprotective Effects

  2022cites this paper
• A new approach in the treatment of traumatic brain injury: The effects of levosimendan on necrosis, apoptosis, and oxidative stress.

  2022cites this paper
• Intranasal levosimendan prevents cognitive dysfunction and apoptotic response induced by repeated isoflurane exposure in newborn rats

  2021cites this paper
• Levosimendan Prevents Memory Impairment Induced by Diabetes in Rats: Role of Oxidative Stress.

  2020cites this paper
• Levosimendan prevents tau pathology by inhibiting disulfide-linked tau oligomerization posing as a promising anti-tau therapeutics

  2020cites this paper
• A 6-Step Approach to Gain Higher Quality Results From Organotypic Hippocampal Brain Slices in a Traumatic Brain Injury Model

  2019cites this paper
• Neuroprotection in Traumatic Brain Injury

  2019cites this paper
• Levosimendan increases brain tissue oxygen levels after cardiopulmonary resuscitation independent of cardiac function and cerebral perfusion

  2019cites this paper
• [Vasopressors and inotropes: use in paediatrics].

  2018cites this paper
• Can Levosimendan Be a Treatment Option in Subarachnoid Hemorrhage?

  2018cites this paper
• Argon attenuates the emergence of secondary injury after traumatic brain injury within a 2-hour incubation period compared to desflurane: an in vitro study

  2017cites this paper
• Efecto de Levosimendan sobre la función cardiaca y renal en el postoperatorio de cirugía cardiaca en pacientes con sindrome de bajo gasto

  2017cites this paper
• Is baseline cerebral oximetry a better predictor than carotid scan for postoperative delirium in cardiac surgery?

  2017cites this paper
• Levosimendan exerts anticonvulsant properties against PTZ‐induced seizures in mice through activation of nNOS/NO pathway: Role for KATP channel

  2017cites this paper
• Levosimendan enhances memory through antioxidant effect in rat model: behavioral and molecular study

  2017cites this paper
• Utilisation du levosimendan chez l’enfant

  2016cites this paper
• Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase.

  2016cites this paper
• Role of levosimendan in the management of subarachnoid hemorrhage.

  2016cites this paper
• [Use of levosimendan in children].

  2016cites this paper
• The preventive role of levosimendan against bleomycin-induced pulmonary fibrosis in rats

  2016cites this paper
• Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase

  2016cites this paper
• Levosimendan, a new therapeutic approach to prevent delayed cerebral vasospasm after subarachnoid hemorrhage?

  2016cites this paper
• Role of PiCCO monitoring for the integrated management of neurogenic pulmonary edema following traumatic brain injury: A case report and literature review.

  2016cites this paper
• Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper.

  2016cites this paper
• Effects of Levosimendan on Hemodynamics, Local Cerebral Blood Flow, Neuronal Injury, and Neuroinflammation After Asphyctic Cardiac Arrest in Rats

  2014cites this paper
• In contrast to its anti-inflammatory and anti-apoptotic peripheral effect, levosimendan failed to induce a long-term neuroprotective effect in a rat model of mild septic encephalopathy: a pilot study.

  2014cites this paper
• Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects

  2013cites this paper
• Functional effects of levosimendan in rat basilar arteries in vitro.

  2013cites this paper
• Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model

  2013cites this paper
• Piperphentonamine (PPTA) attenuated cerebral ischemia-induced memory deficits via neuroprotection associated with anti-apoptotic activity

  2012cites this paper
• Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury

  2012cites this paper
• The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia/hypoxia

  2012cites this paper
• Preoperative regional cerebral oxygen saturation is a predictor of postoperative delirium in on-pump cardiac surgery patients: a prospective observational trial

  2011cites this paper
• Nouvelles approches thérapeutiques pour le traitement de la maladie d'alzheimer

  2010cites this paper